Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.

摘要: Etravirine is an effective and well-tolerated recently approved non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV type-1-infected patients with previous antiretroviral treatment experience. Considering the importance of combining antiretrovirals their optimal use in treating HIV, a number drug-drug interactions etravirine other have been evaluated. weak inducer cytochrome P450 (CYP)3A CYP2C9/CYP2C19 P-glycoprotein, although metabolized by CYP enzyme system, extent clinically relevant limited. can be combined all currently available nucleoside/nucleotide inhibitors without dose adjustments, but not NNRTIs. Available data indicate that coadministered most ritonavir-boosted protease inhibitors. Coadministration tipranavir/ritonavir or unboosted recommended because changes exposure to inhibitor, respectively. integrase elvitegravir/ritonavir raltegravir, fusion enfuvirtide, adjustments. Dose adjustment C-C chemokine receptor type-5 antagonist maraviroc required, type depending on whether boosted included regimen. In conclusion, antiretrovirals, no meaningful effect drug safety/tolerability profiles.